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ABSTRACT 
BACKGROUND 
Chronic venous leg ulcers (VLUs) are costly to the healthcare system and a burden to 
patients, significantly reducing quality of life. Nitric oxide (NO) is important to wound 
healing, with a small study demonstrating a nitric oxide donor, topical glyceryl trinitrate 
(GTN), was effective for VLU healing. The aim of this study is to examine the application of 
topical GTN in relation to VLU healing. 
METHODS 
A pilot double-blinded randomised controlled clinical trial will be undertaken. Participants in 
the control group (n = 20) will receive a placebo ointment (ointment base) and participants in 
the treatment group (n = 20) will receive a nitric oxide donor (base ointment with 0.2% GTN) 
weekly for four weeks. Inclusion criteria: Adults >18 years with a chronic VLU. Rate of 
healing is being determined by planimetry (ulcer tracing) using the Gillman equation.  
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SIGNIFICANCE 
This clinical trial aims to provide proof of concept of a novel treatment, topical GTN, which 
may accelerate wound healing through improvements to vasodilation antimicrobial properties 
at the wound bed.  
WHAT IS ALREADY KNOWN 
• Chronic VLUs are a burden to patients and the healthcare system 
• NO is important to wound healing 
• GTN is a NO donor. 
WHAT THIS STUDY AIMS TO CONTRIBUTE 
• Pilot a double-blind clinical trial of topical GTN 
• Examine the effect of 0.2% topical GTN on wound healing in VLUs.  
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BACKGROUND 
Chronic venous leg ulcers (VLU) are a burden to patients, especially in terms of poorer 
quality of life.1 These ulcers tend to recur, even after an initial healing,2 with up to half of all 
new ulcers lasting more than one year.3 VLU adversely affect quality of life in many ways, 
including via pain and other skin symptoms, disturbed sleep and restriction in social activities 
and mobility.1,4 There is a significant relationship between delayed VLU healing and severely 
reduced quality of life symptoms,1 leading to longer term insomnia, depression and even 
suicidal ideation.5 These factors are also linked to non-adherence to treatment, further 
increasing VLU burden.6 
VLU are also a burden to the community, particularly in terms of increasing healthcare 
costs.3 While there are no recent Australian costing studies, the cost to the Australian health 
budget was estimated to be $365 million per annum in 1994;7 while the cost for the UK in 
2012-13 was £941 million pounds.8 Each VLU in the UK in 2015-16 averaged a cost of 
£7600 over 12 months, which varied from £3000 per healed VLU to £13500 per unhealed 
ulcer; notably unhealed being 4.5 times more costly.3 Although VLU can occur in patients as 
young as 30 years, affecting a person’s work productivity,9 prevalence of these ulcers 
increases with age. This takes on significance in Australia due to an aging population.10 There 
is limited current Australian information on point prevalence of chronic leg ulcers; however, 
a literature review by Bishop and White11 found it varies between 0.1% and 1.1% in the UK. 
Suffice to say there is a need for novel treatments to decrease the burden and costs of VLU to 
patients and society. 
While there are many causes of chronic leg ulcers, venous disease is the most common, 
accounting for nearly 80% of cases.9 While venous insufficiency is the problem,3 the exact 
pathogenesis of venous ulceration is still under investigation. The multiple theories postulated 
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(venous hypertension, fibrin cuff theory, growth factor trap theory, ischaemia/reperfusion 
injury, leukocyte trapping theory)12 indicate the cause is a multifactorial process.3   
In chronic wounds like VLU, the wound healing process is interrupted during the 
inflammatory phase with failure to move towards the repair and remodeling phases. In the 
inflammatory phase, a wound is predominantly infiltrated by macrophages, which, when 
activated, synthesise nitric oxide (NO).13 The wound healing effects of NO at this time 
include vasodilation, antimicrobial activity, antiplatelet effects and induction of vascular 
permeability.13,14 NO production is catalysed by enzymes, including inducible nitric oxide 
synthase (iNOS),14 with peak production occurring within the first 48-72 h of wound healing, 
indicating it is predominantly active during inflammation.13 Impaired wound healing has been 
linked to deficient NO synthesis.13 
A Tasmanian study15 demonstrated that the enzyme (iNOS), which drives the production of 
nitric oxide, was elevated in patients with faster healing VLU. This suggests that application 
of a topical NO donor might accelerate the healing process, by releasing NO into the wound 
to improve blood flow to the affected area and potentially kill unwanted microbes in the 
wound.15 Use of a topical NO donor, glyceryl trinitrate (GTN), strongly demonstrated this, 
but results were inconclusive due to small sample size.15 Given that 30% of ulcers are 
clinically infected on presentation,3 the antimicrobial properties as well as vasodilation from 
NO may be relevant to healing.13 While NO has been trialled in various forms for wound 
healing,14 it has not been used as a topical VLU treatment. Glyceryl trinitrate (GTN) is a NO 
donor which stimulates an increase in the production of NO16 and is already available in an 
ointment formulation approved for human use (Rectogesic, Care Pharmaceuticals). 
Therefore, the aim of this clinical trial is to examine the application of topical GTN ointment 
in relation to the healing of VLU.  
6 
 
METHODS 
Study Design 
This pilot study will utilise a double-blinded randomised controlled clinical trial design. 
Participants in the control group (n = 20) will receive a placebo ointment (ointment base) 
applied weekly for four weeks directly to the venous leg ulcer. Participants in the treatment 
group (n = 20) will receive the nitric oxide donor (ointment base with 0.2% GTN) applied 
weekly. Both ointments have been manufactured to clinical grade by Care Pharmaceuticals. 
Participants and research nurses involved in treatment will not know if the product applied is 
the placebo or the GTN donor. Rate of healing over four weeks will be measured by 
planimetry (ulcer tracing); with complete ulcer healing not likely in the time frame being 
examined. The trial is prospectively registered with the Therapeutic Goods Administration 
(TGA) (Clinical Trial Number (CTN) 2014/0114), and the ANZ Clinical Trial Registry 
(Universal Trial Number U1111-1153-9849). Ethics and site specific governance approval 
have been obtained (HREC/13/QPCH/68; SSA/15/QPCH/244). 
Hypothesis  
Participants receiving the GTN donor ointment will have a statistically higher linear healing 
rate (LHR) compared to patients that receive only the placebo ointment.  
Setting and Sample 
The setting is a 630-bed tertiary referral hospital in southeast Queensland. Participant 
recruitment will be drawn from patients (adults > 18 years) in the hospital’s medical wards, 
who are medically diagnosed with a chronic VLU and who consent to participate. 
Participants with a leg ulcer of non-venous origin, such as arterial, pressure or diabetic will 
be excluded. Other exclusions include patients with malignant ulcers, other forms of 
malignancy, active autoimmune disease, or who have had organ transplantation, or have an 
active exacerbation of cardiac disease.  
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Study Procedure  
Both ointments will be aliquoted by a biochemist into separately coded (coloured dot) 
sterilised jars. Blinding will be achieved with one member of the research team using an 
online random number generator to prepare a set of randomised numbered labels, which will 
be attached to the jars as per coding and numerical sequence. Ointments will be stored with 
the hospital pharmacy and dispensed following recruitment as per medically ordered trial 
prescription according to numbered sequence.  
Usual medical management for patients with VLU , along with weekly ointment application, 
will be used for both groups. All treatment will be provided by research nurses who have 
received specialised training for this trial. 
Photographs of the wound, collected at baseline and weekly, will be used with digital 
software (PictZar® 7.6.1QS) and planimetry (ulcer tracing) to measure ulcer size and 
ascertain linear healing rate. Rate of healing will be calculated using the Gilman17 equation: 
Linear healing rate = Δ A/PxT (cm/week), where Δ A = change in ulcer area (2nd area – 1st 
area), P = mean perimeter of ulcer (1st perimeter + 2nd perimeter/2), T = time between the 
visits. Weekly treatments will continue for four weeks in hospital or in participant’s homes if 
discharged. Participant characteristics and demographic data, as well as type of medical 
management in place for each participant, will also be collected. 
Data Analysis 
Data will be entered into a statistical database (SPSS Version 25, IBM Corp) for analysis and 
used to compare treatment and control group outcomes, to determine if there is any difference 
in healing rates between the groups. Digital images will be analysed using electronic software 
(PictZar® 7.6.1QS). 
POTENTIAL LIMITATIONS 
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Slow and difficult recruitment has been noted in chronic VLU trials,6 including ones with 
which the researchers have been involved. Patients admitted to hospital with VLU as a co-
morbidity are often too unwell to consent and/or participate in a trial and are usually later 
discharged to a community provider for VLU treatment. Those whose primary reason for 
admission is for their VLU usually have an infection or cellulitis3 and may thus be ineligible 
to participate in a research trial. Many patients are reluctant to return to hospital for ‘a 
research visit’, which is most likely a reflection on how a chronic VLU affects mobility and 
mood, with fatigue and depression being common disabling symptoms.1 Non-adherence to 
treatment has been associated with lack of a trusting relationship with healthcare providers,6 
which likely also affects recruitment. Thus, research grant funding will be used to fund 
research nurses to visit participants in their home for weekly visits if discharged before 
completion of the four weekly treatments. 
SIGNIFICANCE 
Given the lengthy healing rate of VLU3 and the long-term effects of these ulcers on a 
patient’s quality of life,1 novel treatments for VLU are needed. An earlier trial suggested that 
the topical application of GTN had a significant effect on increasing the healing rate of 
chronic venous leg ulcers, though results were inconclusive due to small sample size. This 
clinical trial aims to provide proof of concept of this novel treatment in preparation for a 
larger clinical trial. It is anticipated that GTN will accelerate wound healing through 
improvements to vasodilation and blood flow as well as to antimicrobial properties at the 
wound bed. The burden of VLU on patient quality of life may affect the likelihood of patients 
consenting to participate in research trials, which should be taken into consideration for 
future trial planning. 
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